Skip to content

Damora Therapeutics

US · DMRA #3109 by market cap Listed 1970
23.22 -1.08 -4.44%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 7 in the most recent period (2026/Q3).
  • Total institutional ownership rose 2.7 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
114.97% +2.73pp
Institutions
131 +7
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund48.98%
Hedge Fund38.47%
VC/PE Fund19.29%
Private Company6.71%
Public Company1.13%
Individual/Insider0.26%
Government Pension Fund0.18%
Insurance Company0.17%

Top holders as of 2026-09-30

FMR 15.43% · 9.55M sh
Fairmount Funds Management LLC 14.07% · 8.71M sh
Avoro Capital Advisors LLC 6.11% · 3.78M sh
VR Management, LLC 5.82% · 3.60M sh
BlackRock 5.68% · 3.51M sh
Forbion Capital Partners B.V. 3.94% · 2.44M sh
RA Capital Management, L.P. 3.88% · 2.40M sh
Viking Global Investors LP 3.73% · 2.31M sh
Janus Henderson Group plc 3.69% · 2.28M sh
Panorama Holdings, LLC 3.30% · 2.05M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 34 buys · 11 sells

NameRoleStake
Fairmount Funds Management LLC -- 14.07%
Julianne Bruno Independent Director 0.22%
Jennifer Jarrett Chief Executive Officer 0.02%
Hans Schambye Co-Founder, Former President, CEO & Director 0.01%
Garrett Winslow Senior Vice President 0.00%
Lori Firmani Former Chief Financial Officer 0.00%
Jonathan Freve Former Chief Financial Officer 0.00%
Carl Goldfischer Former Independent Director --
David Shapiro Former Independent Director --
Amy Wechsler Former Independent Director --
Amit Munshi Former Independent Director --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-24 Jennifer Jarrett Chief Executive Officer Open Market Acquisition +12,500 $20.23
2026-08-11 Andrew Cheng Director Other Derivative Acquisition +30,350 $31.00
2026-08-04 Lori Firmani Former Chief Financial Officer Intent to Sell (Form 144) -1,800 $31.10
2026-07-05 Garrett Winslow Senior Vice President Derivative Exercise and Sale -245 $29.98
2026-07-02 Garrett Winslow Senior Vice President Derivative Exercise and Retained +435 --
2026-06-21 Lori Firmani Former Chief Financial Officer Intent to Sell (Form 144) -7,615 $25.36
2026-04-30 Brian Burkavage Senior VP of Finance, Principal Financial & Accounting Officer Initial Statement of Beneficial 0 --
2026-03-29 Jennifer Jarrett Chief Executive Officer Other Acquisition +500,000 --
2026-03-29 Jennifer Jarrett Chief Executive Officer Other Derivative Acquisition +1,500,000 $25.50
2026-03-22 Michael Landsittel Independent Director Other Derivative Acquisition +37,313 $23.05
2026-03-22 Christopher Cain Independent Director Other Derivative Acquisition +37,313 $23.05
2026-03-22 Garrett Winslow Senior Vice President Other Derivative Acquisition +250,000 $23.05
2026-03-22 Cameron Turtle Independent Director Other Derivative Acquisition +37,313 $23.05
2026-03-22 Peter Harwin Independent Chairperson Other Derivative Acquisition +37,313 $23.05
2026-03-22 Julianne Bruno Independent Director Other Derivative Acquisition +37,313 $23.05
2026-02-08 Fairmount Funds Management LLC -- Derivative Exercise and Retained +8,713,000 --
2026-02-08 Julianne Bruno Independent Director Derivative Exercise and Retained +129,000 --
2026-01-04 Becker Hewes Chief Medical Officer Other Acquisition +264,629 --
2026-01-04 Becker Hewes Chief Medical Officer Other Derivative Acquisition +528,603 $21.82
2026-01-04 Sherwin Sattarzadeh Chief Operating Officer Other Acquisition +190,376 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Damora Therapeutics discussion 0 comments

Add a comment